 Early in the 1980s MET was described as the protein product of a transforming oncogene.Initial attempts to identify ATP-competitive c-Met inhibitors in 2002 led to the discovery of K252a, a staurosporine-like inhibitor which blocks c-Met.K252a was the first structure to be solved in complex with the unphosphorylated MET kinase domain.